© 2022 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
August 28, 2008
The benefits of implantable cardioverter-defibrillators (ICDs) have been shown in randomized clinical trials. The factors that affect the risk–benefit ratio in a community setting, however, have not been evaluated.
Wonder Drake, MD: Sarcoidosis is a Disease of Exclusion
FDA Approves Dupilumab for Eosinophilic Esophagitis
New 52-Week Data Finds Guselkumab Well Tolerated in Moderate to Severe Psoriasis